• Ismail Mccray posted an update 6 months, 3 weeks ago

    Fluorescence decay-associated spectra at 77 K showed distinct excitation-energy-quenching components and alterations of energy-transfer pathways in the FCP complexes under the HL condition. These findings provide insights into molecular and functional mechanisms of the dynamic regulation of FCPs in this diatom under excess-light conditions.Carotenoids (Cars) regulate the energy flow towards the reaction centres in a versatile way whereby the switch between energy harvesting and dissipation is strongly modulated by the operation of the xanthophyll cycles. However, the cascade of molecular mechanisms during the change from light harvesting to energy dissipation remains spectrally poorly understood. By characterizing the in vivo absorbance changes (ΔA) of leaves from four species in the 500-600 nm range through a Gaussian decomposition, while measuring passively simultaneous Chla fluorescence (F) changes, we present a direct observation of the quick antenna adjustments during a 3-min dark-to-high-light induction. Underlying spectral behaviours of the 500-600 nm ΔA feature can be characterized by a minimum set of three Gaussians distinguishing very quick dynamics during the first minute. Our results show the parallel trend of two Gaussian components and the prompt Chla F quenching. Further, we observe similar quick kinetics between the relative behaviour of these components and the in vivo formations of antheraxanthin (Ant) and zeaxanthin (Zea), in parallel with the dynamic quenching of singlet excited chlorophyll a (1Chla*) states. After these simultaneous quick kinetical behaviours of ΔA and F during the first minute, the 500-600 nm feature continues to increase, indicating a further enhanced absorption driven by the centrally located Gaussian until 3 min after sudden light exposure. Observing these precise underlying kinetic trends of the spectral behaviour in the 500-600 nm region shows the large potential of in vivo leaf spectroscopy to bring new insights on the quick redistribution and relaxation of excitation energy, indicating a key role for both Ant and Zea.

    To compare pain levels and medication needs after placement of laminaria vs Dilapan-S, and after dilation and evacuation (D&E).

    We conducted a single-blinded randomized control trial of patients undergoing D&E at 15 0/7 to 23 6/7 weeks gestation, randomizing to cervical preparation with laminaria or Dilapan-S. We compared pain levels and medication usage following dilator placement (5 minutes; 2, 4, and 8 hours; the following morning) and D&E (1, 4, 24, and 48 hours). Our primary outcome was median change from baseline pain, and secondary outcomes included maximum pain timing and overall narcotic use. We compared baseline characteristics, median pain increases and quantities of narcotics used.

    We analyzed 67 participants with laminaria (n=34) and Dilapan-S (n=33). Dibenzazepine manufacturer More Dilapan-S users had a prior vaginal delivery (n=20, 60.6%) than laminaria users (n=11, 32.4%), p=0.02. Maximum median pain was not statistically different (Laminaria +3.5 (interquartile range +0.5, +6.5); Dilapan-S +3 (Ia small amount of narcotics during their D&E episode, pain management should be individualized to patient needs.Cervical preparation with laminaria reduces complications with 2nd trimester dilation and evacuation. During a surgical abortion at 22 weeks, we could not remove laminaria manually or with ring forceps due to laminaria “dumbbelling” . Without pushing laminaria into the uterus, we mechanically dilated the cervix and removed the incarcerated laminaria.

    Very short interpregnancy intervals are associated with negative health outcomes for mothers and children, and pregnancies with very short interpregnancy intervals are more likely to be unintended than pregnancies that are more widely spaced. The objective of this study was to improve understanding of women’s motivations regarding pregnancy spacing.

    In 2017, we conducted 8 focus group discussions with 49 English- and Spanish-speaking postpartum women in central North Carolina. The groups explored participants’ preferences for birth spacing and factors that influenced their decisions. We recorded, transcribed, and coded the discussions and analyzed these data for core themes.

    Participants’ ideas about when and whether to have more children were fluid-some had specific ideas during pregnancy or after delivery that changed over time; others had no definite plans. The primary reason for close birth spacing was to promote their children’s having a closer relationship. Reasons for wider spacing included recovery from the previous pregnancy, challenges related to having 2 babies concurrently, and desire to wait for more favorable life circumstances. Participants did not mention health risks to children of short interpregnancy intervals and said that no health care providers discussed these risks with them. They had mixed perspectives about whether this information would influence their own child-spacing preferences but agreed that it should be shared with women to promote informed decision-making.

    This study adds to limited research regarding the factors that women consider when determining pregnancy spacing. Better understanding of women’s motivations can help inform counseling to help women achieve their desired pregnancy spacing.

    This study adds to limited research regarding the factors that women consider when determining pregnancy spacing. Better understanding of women’s motivations can help inform counseling to help women achieve their desired pregnancy spacing.

    First-line durvalumab plus etoposide with either cisplatin or carboplatin (platinum-etoposide) showed a significant improvement in overall survival versus platinum-etoposide alone in patients with extensive-stage small-cell lung cancer (ES-SCLC) in the CASPIAN study. Here we report updated results, including the primary analysis for overall survival with durvalumab plus tremelimumab plus platinum-etoposide versus platinum-etoposide alone.

    CASPIAN is an ongoing, open-label, sponsor-blind, randomised, controlled phase 3 trial at 209 cancer treatment centres in 23 countries worldwide. Eligible patients were aged 18 years or older (20 years in Japan) and had treatment-naive, histologically or cytologically documented ES-SCLC, with a WHO performance status of 0 or 1. Patients were randomly assigned (111) in blocks of six, stratified by planned platinum, using an interactive voice-response or web-response system to receive intravenous durvalumab plus tremelimumab plus platinum-etoposide, durvalumab plus platinum-etoposide, or platinum-etoposide alone.

All content contained on CatsWannaBeCats.Com, unless otherwise acknowledged,is the property of CatsWannaBeCats.Com and subject to copyright.

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Log in with your credentials

or    

Forgot your details?

Create Account